See the DrugPatentWatch profile for cosentyx

Based on the information available, it is recommended to consult with a healthcare provider before administering live vaccines during Cosentyx (secukinumab) therapy [1]. Cosentyx is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2]. It is a type of drug called a monoclonal antibody that works by targeting a specific molecule in the body called interleukin-17A (IL-17A) [1].

According to the drug's prescribing information, the use of live vaccines should be avoided in patients receiving Cosentyx [1]. This is because Cosentyx may affect a person's immune system and reduce their ability to respond to live vaccines [1]. Additionally, there is a risk of developing infections from live vaccines in patients receiving immunosuppressive therapies like Cosentyx [1].

It is important to note that the safety and efficacy of Cosentyx in combination with live vaccines have not been studied [1]. Therefore, it is recommended to consult with a healthcare provider to determine the most appropriate vaccination schedule and timing of Cosentyx therapy [1].

In summary, based on the available information, it is not recommended to administer live vaccines during Cosentyx therapy due to the potential risks associated with immunosuppressive therapies [1]. It is crucial to consult with a healthcare provider to determine the most appropriate vaccination schedule and timing of Cosentyx therapy.

Sources:

* [1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* [2] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.